Affinia Therapeutics
Waltham
About Affinia Therapeutics
Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $210.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Oct 2025)
- Website: affiniatx.com
- Phone: 617-430-7817
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/affinia-therapeutics-104492 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.